Panacea Biotec gains on getting Award notification from Pan American Health Organization
Panacea Biotec is currently trading at Rs 399.90, up by 3.50 points or 0.88% from its previous closing of Rs 396.40 on the BSE.
The scrip opened at Rs 407.05 and has touched a high and low of Rs 407.05 and Rs 398.50 respectively. So far 2655 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 1 has touched a 52-week high of Rs 581.00 on 15-May-2025 and a 52-week low of Rs 282.15 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs 433.70 and Rs 394.65 respectively. The current market cap of the company is Rs 2449.42 crore.
The promoters holding in the company stood at 72.48%, while Institutions and Non-Institutions held 2.86% and 24.66% respectively.
Panacea Biotec has received an Award notification from Pan American Health Organization, (PAHO) Regional Office of World Health Organization under a Long-term agreement for supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) - Liquid (single dose) (Easyfive-TT) to PAHO, valid until December 31, 2027.
The total award to the company is for supply of Easyfive-TT Vaccine aggregating around $4.75 million (around Rs.41 crore) during Calendar Year 2026 and 2027.
Panacea Biotec is a leading research-based Biotechnology Company with established research, manufacturing and marketing capabilities.
